Showing 2191-2200 of 5064 results for "".
- Study: HA Fillers Effective for Full-face Rejuvenationhttps://practicaldermatology.com/news/20120824-study_ha_fillers_effective_for_full-face_rejuvenation/2459747/In subjects with multiple indications, full-face rejuvenation using hyaluronic acid (HA) fillers” provided effective, safe, and satisfactory results,” one of the first studies of its kind concludes. (Dermatol Surg;38(7 Pt 2):1153-61) The six-month study involved 77 subjects treated with five differe
- ASDS Annual Meeting Sessions Announced, Early Registration Discounthttps://practicaldermatology.com/news/20120808-asds_annual_meeting_sessions_announced_early_registration_discount/2459754/The 2012 Annual Meeting of the American Society for Dermatologic Surgery (ASDS) will be held from October 11 to 14 in Atlanta, GA. The 65-plus scientific and educational sessions are divided into four comprehensive curriculum tracks: co
- Neodyne Biosciences Announces Positive Interim Trial Results for Embracehttps://practicaldermatology.com/news/20120807-neodyne_biosciences_announces_positive_interim_trial_results_for_embrace/2459756/Neodyne Biosciences, Inc. announced positive interim results from the REFINE Trial (Scar Prevention and the Clinical Effectiveness of a Novel Mechano-modulating Polymer), a randomized, control clinical trial designed to assess the efficacy and
- Abbott 2Q Profit Beats Expectations, Humira Sales Growhttps://practicaldermatology.com/news/20120802-abbott_2q_profit_beats_expectations_humira_sales_grow/2459757/Abbott Laboratories announced that second-quarter earnings narrowly beat estimates, fueled by the continued growth of its drug Humira. The company said net income for the quarter declined to $1.75 billion, or $1.08 per share, from $1.94 b
- National Rosacea Society to Host 20th Anniversary Galahttps://practicaldermatology.com/news/20120730-national_rosacea_society_to_host_20th_anniversary_gala/2459759/The National Rosacea Society is hosting a 20th Anniversary Gala Celebration and Dinner on August 17, 2012, from 6-9pm at the Boston Sheraton Hotel during the summer AAD meeting to give thanks to the countless healthcare professionals who have helped improve the quality of life for rosacea patients w
- DASIL Announces Inaugural Congresshttps://practicaldermatology.com/news/20120725-dasil_announces_inaugural_congress/2459763/The Dermatologic & Aesthetic Surgery International League (DASIL), headquartered in Chicago, Illinois, is hosting its first annual DASIL Congress, to be held on the island of Malta, from October 31 to November 4, 2012. This international dermatol
- Pycnogenol Improves Visible Signs of Aginghttps://practicaldermatology.com/news/20120718-pycnogenol_improves_visible_signs_of_aging/2459770/Pycnogenol is effective in improving visible signs of skin aging in women aged 55 to 68 years, according to a study published in a recent issue of Skin Pharmacology and Physiology. The study found that after 12 weeks of supplementing with Pycno
- Galderma's Cetaphil Celebrates 65 Yearshttps://practicaldermatology.com/news/20120711-galdermas_cetaphil_celebarates_65_years/2459775/Galderma's Cetaphil Gentle Skin Cleanser is celebrating 65 years on the market. Introduced in 1947 as Cetaphil Cleansing Lotion, it was initially developed by a pharmacist for use as a compounding base. By the 1960s, the product was so popular t
- Ulthera Announces Indication for Decolletage in Asiahttps://practicaldermatology.com/news/20120709-ulthera_announces_indication_for_dcolletage_in_asia/2459776/Ulthera, Inc., a global, growth-stage medical device company, announced the commercial availability of the Ulthera System in select Asian countries to non-invasively treat the skin on the chest area, or décolletage. The Ulthera Sys
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33